Kazia Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Kazia Therapeutics has a total shareholder equity of A$-10.0M and total debt of A$634.0K, which brings its debt-to-equity ratio to -6.3%. Its total assets and total liabilities are A$21.6M and A$31.6M respectively.
Key information
-6.3%
Debt to equity ratio
AU$634.00k
Debt
| Interest coverage ratio | n/a |
| Cash | AU$1.66m |
| Equity | -AU$10.02m |
| Total liabilities | AU$31.60m |
| Total assets | AU$21.59m |
Recent financial health updates
Recent updates
Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy
Jul 06Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial
Jun 15Enrollment gets underway in Kazia's mid-stage lymphoma study
Jun 07Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer
Dec 10Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study
Dec 09Kazia stock +22% on positive paxalisib data in glioblastoma
Nov 18Financial Position Analysis
Short Term Liabilities: KZIA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: KZIA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: KZIA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: KZIA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KZIA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: KZIA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.6% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:58 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kazia Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Soo Romanoff | Edison Investment Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |